Valneva (VLA) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenues rose 50.3% year-over-year to €49.2 million, with product sales up 51.2% to €48.6 million, driven by recovery from supply shortages and strong demand.

• Net loss was €9.2 million, reversing a prior year profit that included a €90.8 million one-time Priority Review Voucher sale.

• Operating cash burn reduced by 71% to €8.1 million, with cash and cash equivalents at €153 million at quarter-end, excluding €14.2 million from an April ATM transaction.

• Achieved significant regulatory milestones for IXCHIQ, including label extensions, new approvals in the UK, Europe, and Brazil, and a new IXIARO contract with the US Department of Defense.

• Advanced clinical pipeline with positive IXCHIQ data in adolescents and pediatrics, and initiated phase II studies for Shigella and ZIKA vaccine candidates.

Financial highlights

• Product sales reached €48.6 million, up 51.2% year-over-year; IXIARO/JESPECT sales rose 65.5% to €27.5 million, DUKORAL sales grew 9.4% to €12.3 million, and IXCHIQ sales increased to €3.0 million.

• Gross margin on commercial products (excluding IXCHIQ) improved to 62.7% from 43.9% year-over-year; IXIARO gross margin reached 72.6%, DUKORAL 52.2%.

• Adjusted EBITDA was €(0.6) million, compared to €73.0 million in Q1 2024, which included a one-time €90.8 million gain from a PRV sale.

• Operating loss was €6 million; net loss for Q1 2025 was €9.2 million.

• R&D expenses increased to €15.0 million from €13.1 million year-over-year.

Outlook and guidance

• FY2025 product sales guidance reiterated at €170–180 million and total revenues at €180–190 million.

• R&D expenses expected between €90–100 million, partially offset by grants and tax credits.

• Targeting operational cash burn below €30 million, more than 50% lower than 2024, with a path to sustained profitability from 2027 based on successful Lyme vaccine commercialization.

• Commercial business expected to be cash-flow positive, with focus on gross margin improvement and cost-efficient manufacturing.